ProMIS Neurosciences, Inc.
NASDAQ:PMNBiotechnology
-$0.02 today
- Market cap
- $99.36M
- Beta
- -0.22
- P/E (TTM)
- -0.6
- EPS (TTM)
- -$4.62
Volume 0.13M
Average 0.07M
PMN Income Before Tax
Profit after all operating and non-operating items but before income tax.
ProMIS Neurosciences, Inc.NASDAQ: PMN
Income Before Tax · Q2 FY2026 · quarter ended Jun 2026
Income before tax remains negative
Q2 FY2026 income before tax was -$11.73M, compared with -$10.12M a year earlier. Trailing-twelve-month income before tax was -$42.23M.
Context
- Income before tax increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly income before tax holds near -$11.73M or moves back toward the trailing-twelve-month quarterly average of -$10.56M.
Sources:Income StatementText generated from reported figures; not investment advice.
Income Before Tax history
Mixed currencies · from the income statement
- Latest · FY2025
- (39.72M) USD
- Year-over-year change
- -1529.3%
| Period | Period end | Income Before Tax | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (39.72M) | -1529.3% |
| FY2024 | 2024-12-31 | 2.78M | +115.9% |
| FY2023 | 2023-12-31 | (17.51M) | — |
| FY2022 | 2022-12-31 | (18.06B) | -144660.6% |
| FY2021 | 2021-12-31 | (12.48M) | — |
Income Before Tax vs competitors
How PMN compares with its peers on the latest reported figures
- PMN's LTM Jun 2026 income before tax of -$42.23M is the 2nd highest of the 4 companies compared; the peer median is -$53.42M.
- Its year-over-year change of -401.1% is the lowest of 3, against a peer median of -112.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$10.44M | -78.9% | — | — | |
| LTM Jun 2026 | -$42.23M | -401.1% | — | — | |
| LTM Jun 2024 | -$53.42M | — | — | 823.1% | |
| LTM Mar 2026 | -$199.48M | -146.3% | — | — | |
| Peer median (excluding PMN) | -$53.42M | -112.6% | — | 823.1% | |
Competitors are the stored peer set for PMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 · CAD | FY2022 Dec 2022 · CAD | FY2023 Dec 2023 · USD | FY2024 Dec 2024 · USD | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Revenue | 16.68K | 0 | 0 | 0 | 0 |
| Cost of Revenue | 5.85M | 0 | 10.44M | 0 | 0 |
| Gross Profit | (5.84M) | 0 | (10.44M) | 0 | 0 |
| Gross Margin | -35031.9% | — | — | — | — |
| Research & Development | 4.95M | 16.09B | 7.88M | 10.64M | 33.38M |
| Selling, General & Admin | 3.31M | 7.29B | 6.38M | 6.19M | 6.79M |
| Operating Expenses | 4.63M | 23.38B | 8.45M | 16.83M | 40.17M |
| Depreciation & Amortization | 45.83K | 0 | 28.04K | 0 | 0 |
| EBITDA | (9.33M) | (17.78B) | (17.81M) | 2.86M | (39.72M) |
| EBITDA Margin | -55923.2% | — | — | — | — |
| Operating Income | (10.57M) | (23.38B) | (18.9M) | (16.83M) | (40.17M) |
| Operating Margin | -63350.5% | — | — | — | — |
| Interest Income | 4.73K | 0 | 0 | 0 | 0 |
| Interest Expense | 416.29K | 282.06M | 201.39K | 76.78K | 0 |
| Other Income / Expenses | (1.91M) | 5.32B | 1.39M | 19.61M | 448.16K |
| Income Before Tax | (12.48M) | (18.06B) | (17.51M) | 2.78M | (39.72M) |
| Pre-Tax Margin | -74804.2% | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (11.98M) | (18.06B) | (17.51M) | 2.78M | (39.72M) |
| Net Margin | -71819.3% | — | — | — | — |
| EPS (Basic) | (51.77) | (60.25) | (35.50) | 2.75 | (22.61) |
| EPS (Diluted) | (51.77) | (60.25) | (35.50) | 2.75 | (22.61) |
| Weighted Avg Shares | 231.42K | 300.1K | 491.71K | 1.04M | 1.76M |
| Weighted Avg Shares (Diluted) | 231.43K | 300.1K | 491.71K | 1.06M | 1.76M |
ProMIS Neurosciences, Inc.
NASDAQ:PMN
Intrinsic Alpha fair value
Locked
Current Price
$11.08
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.